These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28247316)

  • 1. Selecting Potential Pharmacological Interventions in Sarcopenia.
    Kilsby AJ; Sayer AA; Witham MD
    Drugs Aging; 2017 Apr; 34(4):233-240. PubMed ID: 28247316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal management of sarcopenia.
    Burton LA; Sumukadas D
    Clin Interv Aging; 2010 Sep; 5():217-28. PubMed ID: 20852669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia.
    Sakuma K; Yamaguchi A
    Pflugers Arch; 2018 Mar; 470(3):449-460. PubMed ID: 29043432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic considerations of sarcopenia in heart failure patients.
    Saitoh M; Ebner N; von Haehling S; Anker SD; Springer J
    Expert Rev Cardiovasc Ther; 2018 Feb; 16(2):133-142. PubMed ID: 29308681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).
    Spira D; Walston J; Buchmann N; Nikolov J; Demuth I; Steinhagen-Thiessen E; Eckardt R; Norman K
    Drugs Aging; 2016 Nov; 33(11):829-837. PubMed ID: 27665105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations in the development of drugs to treat sarcopenia.
    Brass EP; Sietsema KE
    J Am Geriatr Soc; 2011 Mar; 59(3):530-5. PubMed ID: 21361879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future pharmacologic treatment of sarcopenia.
    Rolland Y; Onder G; Morley JE; Gillette-Guyonet S; Abellan van Kan G; Vellas B
    Clin Geriatr Med; 2011 Aug; 27(3):423-47. PubMed ID: 21824556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies.
    Zheng Y; Feng J; Yu Y; Ling M; Wang X
    Arch Pharm Res; 2024 Apr; 47(4):301-324. PubMed ID: 38592582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Literature Review on the Relationship Between Biomarkers of Sarcopenia and Quality of Life in Older People.
    Woo T; Yu S; Visvanathan R
    J Frailty Aging; 2016; 5(2):88-99. PubMed ID: 27224499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Options for the Treatment of Sarcopenia.
    Morley JE
    Calcif Tissue Int; 2016 Apr; 98(4):319-33. PubMed ID: 26100650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myostatin and sarcopenia: opportunities and challenges - a mini-review.
    White TA; LeBrasseur NK
    Gerontology; 2014; 60(4):289-93. PubMed ID: 24457615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current pharmacotherapies for sarcopenia.
    Hardee JP; Lynch GS
    Expert Opin Pharmacother; 2019 Sep; 20(13):1645-1657. PubMed ID: 31120352
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease.
    Marty E; Liu Y; Samuel A; Or O; Lane J
    Bone; 2017 Dec; 105():276-286. PubMed ID: 28931495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice.
    Camporez JP; Petersen MC; Abudukadier A; Moreira GV; Jurczak MJ; Friedman G; Haqq CM; Petersen KF; Shulman GI
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2212-7. PubMed ID: 26858428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan.
    Tanimoto Y; Watanabe M; Sun W; Sugiura Y; Tsuda Y; Kimura M; Hayashida I; Kusabiraki T; Kono K
    Arch Gerontol Geriatr; 2012; 55(2):e9-13. PubMed ID: 22795189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regenerative Medicine Approaches for Age-Related Muscle Loss and Sarcopenia: A Mini-Review.
    Naranjo JD; Dziki JL; Badylak SF
    Gerontology; 2017; 63(6):580-589. PubMed ID: 28813700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in sarcopenia: A multifactorial approach.
    Curcio F; Ferro G; Basile C; Liguori I; Parrella P; Pirozzi F; Della-Morte D; Gargiulo G; Testa G; Tocchetti CG; Bonaduce D; Abete P
    Exp Gerontol; 2016 Dec; 85():1-8. PubMed ID: 27633530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?
    Sumukadas D; Struthers AD; McMurdo ME
    Gerontology; 2006; 52(4):237-42. PubMed ID: 16849867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frailty and sarcopenia in Bogotá: results from the SABE Bogotá Study.
    Samper-Ternent R; Reyes-Ortiz C; Ottenbacher KJ; Cano CA
    Aging Clin Exp Res; 2017 Apr; 29(2):265-272. PubMed ID: 27034288
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.